TN2011000207A1 - Akt and p70 s6 kinase inhibitors - Google Patents

Akt and p70 s6 kinase inhibitors

Info

Publication number
TN2011000207A1
TN2011000207A1 TN2011000207A TN2011000207A TN2011000207A1 TN 2011000207 A1 TN2011000207 A1 TN 2011000207A1 TN 2011000207 A TN2011000207 A TN 2011000207A TN 2011000207 A TN2011000207 A TN 2011000207A TN 2011000207 A1 TN2011000207 A1 TN 2011000207A1
Authority
TN
Tunisia
Prior art keywords
akt
kinase inhibitors
formula
compounds
present
Prior art date
Application number
TN2011000207A
Other languages
English (en)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TN2011000207A1 publication Critical patent/TN2011000207A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2011000207A 2008-11-11 2011-04-25 Akt and p70 s6 kinase inhibitors TN2011000207A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
PCT/US2009/063020 WO2010056563A1 (fr) 2008-11-11 2009-11-03 Inhibiteurs de kinase akt et p70 s6

Publications (1)

Publication Number Publication Date
TN2011000207A1 true TN2011000207A1 (en) 2012-12-17

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000207A TN2011000207A1 (en) 2008-11-11 2011-04-25 Akt and p70 s6 kinase inhibitors

Country Status (37)

Country Link
US (1) US8148387B2 (fr)
EP (1) EP2358710B1 (fr)
JP (1) JP5432275B2 (fr)
KR (1) KR101334460B1 (fr)
CN (1) CN102216302B (fr)
AR (1) AR074072A1 (fr)
AU (1) AU2009314324B2 (fr)
BR (1) BRPI0921916A2 (fr)
CA (1) CA2743019C (fr)
CO (1) CO6382114A2 (fr)
CR (1) CR20110240A (fr)
CY (1) CY1113409T1 (fr)
DK (1) DK2358710T3 (fr)
DO (1) DOP2011000129A (fr)
EA (1) EA018947B1 (fr)
EC (1) ECSP11011048A (fr)
ES (1) ES2391704T3 (fr)
HK (1) HK1158203A1 (fr)
HN (1) HN2011001247A (fr)
HR (1) HRP20120738T1 (fr)
IL (1) IL211940A (fr)
JO (1) JO2822B1 (fr)
MA (1) MA32776B1 (fr)
MX (1) MX2011005000A (fr)
MY (1) MY161461A (fr)
NZ (1) NZ592062A (fr)
PA (1) PA8846901A1 (fr)
PE (1) PE20110807A1 (fr)
PL (1) PL2358710T3 (fr)
PT (1) PT2358710E (fr)
RS (1) RS52520B (fr)
SI (1) SI2358710T1 (fr)
TN (1) TN2011000207A1 (fr)
TW (1) TWI422587B (fr)
UA (1) UA100190C2 (fr)
WO (1) WO2010056563A1 (fr)
ZA (1) ZA201102549B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177469A1 (en) 2009-07-02 2012-02-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Ａｋｔ阻害剤
CA2832374A1 (fr) 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines en tant qu'inhibiteurs de la kinase akt
US8927572B2 (en) * 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
DK2755958T3 (en) 2011-09-12 2017-09-25 Merck Patent Gmbh AMINOPYRIMIDINE DERIVATIVES USED AS MODULATORS OF KINASE ACTIVITY
SG10201606301YA (en) 2011-09-12 2016-09-29 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
WO2014078634A1 (fr) 2012-11-16 2014-05-22 Merck Patent Gmbh Nouveaux dérivés imidazol-pipéridinyle en tant que modulateurs de l'activité kinase
CA2890288A1 (fr) 2012-11-16 2014-05-22 Merck Patent Gmbh Nouveaux derives heterocycliques comme modulateurs de l'activite kinase
SG11201505999VA (en) 2013-03-11 2015-08-28 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
RU2690679C2 (ru) * 2014-02-11 2019-06-05 Мерк Патент Гмбх Новые пиримидинимидазоламины в качестве модуляторов активности киназы
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
DK3459953T3 (da) * 2016-05-20 2021-08-23 Taiho Pharmaceutical Co Ltd Hidtil ukendt 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-on-derivat
TW202136269A (zh) * 2020-03-17 2021-10-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合二環類衍生物、其製備方法及其在醫藥上的應用
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CA3231865A1 (fr) 2021-09-17 2023-03-23 Tingting SHANG Derive bicyclique fusionne, sel pharmaceutiquement acceptable, forme cristalline de celui-ci et son procede de preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750727A2 (fr) 2004-04-23 2007-02-14 Exelixis, Inc. Modulateurs des proteines kinases et leurs methodes d'utilisation
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006091450A1 (fr) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated Composes 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine
WO2007003960A1 (fr) 2005-06-30 2007-01-11 Prosidion Limited Agonistes du gpcr
EP2043655A2 (fr) 2006-04-25 2009-04-08 Astex Therapeutics Limited Derives de purine et de deazapurine comme composes pharmaceutiques
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
WO2008012635A2 (fr) 2006-07-26 2008-01-31 Pfizer Products Inc. Dérivés d'amines utiles en tant qu'agents anticancéreux
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
MX2011005000A (es) 2011-05-25
AR074072A1 (es) 2010-12-22
CR20110240A (es) 2011-06-09
MY161461A (en) 2017-04-14
WO2010056563A1 (fr) 2010-05-20
SI2358710T1 (sl) 2012-11-30
US8148387B2 (en) 2012-04-03
US20100120801A1 (en) 2010-05-13
KR20110074578A (ko) 2011-06-30
JO2822B1 (en) 2014-09-15
PE20110807A1 (es) 2011-10-31
DOP2011000129A (es) 2016-02-29
PT2358710E (pt) 2012-10-01
DK2358710T3 (da) 2012-09-03
BRPI0921916A2 (pt) 2015-12-29
CA2743019C (fr) 2013-08-13
JP2012508274A (ja) 2012-04-05
NZ592062A (en) 2013-03-28
EP2358710B1 (fr) 2012-08-15
ECSP11011048A (es) 2011-06-30
TWI422587B (zh) 2014-01-11
CO6382114A2 (es) 2012-02-15
MA32776B1 (fr) 2011-11-01
IL211940A (en) 2014-01-30
UA100190C2 (en) 2012-11-26
CN102216302A (zh) 2011-10-12
JP5432275B2 (ja) 2014-03-05
EP2358710A1 (fr) 2011-08-24
AU2009314324B2 (en) 2013-06-20
HRP20120738T1 (hr) 2012-10-31
RS52520B (en) 2013-04-30
CN102216302B (zh) 2013-08-21
TW201022268A (en) 2010-06-16
EA018947B1 (ru) 2013-11-29
ZA201102549B (en) 2012-09-26
HK1158203A1 (en) 2012-07-13
EA201170680A1 (ru) 2011-12-30
KR101334460B1 (ko) 2013-12-02
ES2391704T3 (es) 2012-11-29
CY1113409T1 (el) 2016-06-22
HN2011001247A (es) 2013-05-20
AU2009314324A1 (en) 2010-05-20
PL2358710T3 (pl) 2012-12-31
CA2743019A1 (fr) 2010-05-20
IL211940A0 (en) 2011-06-30
PA8846901A1 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TN2009000446A1 (en) P70 s6 kinase inhibitors
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
MX2012004780A (es) Inhibidores de akt.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MY153915A (en) Organic compounds
MY148634A (en) Pyridazinone derivatives
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
MY181898A (en) Heterocyclic compounds and uses thereof
MY146989A (en) Kinase inhibitors
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
WO2012122383A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
TNSN08191A1 (en) Kinase inhibitors
UA85505C2 (en) Kinase inhibitors
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
WO2010077730A3 (fr) Inhibiteurs indanones de l'acétylcholinestérase
WO2010059639A3 (fr) Inhibiteurs à base d'hydroxyadamantyle de dipeptidylpeptidase iv
WO2009114856A3 (fr) Inhibiteurs des aurora kinases